PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.
Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.
The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.
The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
A user is treating their advanced hair loss with a regimen including topical finasteride, minoxidil, hydrocortisone, stem cell serum, peptide serum, multivitamins, he shou wu tea, derma pen, argan oil, and a derma roller. Replies suggest it's too early to judge progress and recommend staying consistent, with one suggesting oral minoxidil as an additional option.
The conversation discusses a new study on topical pumpkin seed oil for hair loss in mice. Treatments mentioned include Minoxidil, finasteride, and RU58841.
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
Kintor 0.9% is not effective for hair regrowth or thickening and may cause testicle sensitivity. The conversation criticizes the hype around Kintor and discusses the ineffectiveness of pyrilutamide compared to other treatments like RU58841, finasteride, and minoxidil.
User has been using 1.25 mg finasteride and 2.5 mg minoxidil daily for 5 months, along with 5000 mcg biotin for 1.5 months. They noticed peach fuzz growth around month 4 and are seeking confirmation if this indicates hair regrowth.
CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.
User noticed tiny dots on their head after using 0.5% dutasteride and 8% minoxidil, which others identified as developing hair follicles. Encouragement was given to continue the treatment.
Microneedling can enhance hair growth results when combined with finasteride and minoxidil, with noticeable improvements in 1-2 weeks. The derminator 2.0 is recommended for best results.
The user experienced significant hair regrowth using 1.25mg finasteride daily and 5% topical minoxidil nightly, with no major side effects or shedding. The progress is evident, especially around the temple area, and the user is hopeful for continued growth.
ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.
A user reports significant hair density increase and new growth at the temples after two months of using finasteride, minoxidil, ketoconazole, dermarolling, MK-677, zinc, and vitamin D3, with shedding stopping a week ago. They recently added MK-677 to their regimen.
The user is experiencing a second hair shedding phase and increased flaking and itching while using minoxidil 5% nightly and microneedling every two weeks, with needle length increasing over time. Other users suggest the hair loss may continue without the use of finasteride.
The conclusion of the conversation is that CosmeRna may not be an effective treatment for hair loss compared to topical minoxidil 2%. It is suggested to wait for more reviews before purchasing it.
A user from Iran reports hair growth in bald spots after using a domestic tonic containing Anageline, Trichogen, Aminexil, Caffeine, Saw Palmetto, and B vitamins, alongside Finasteride, but without Minoxidil. They prefer the tonic over Minoxidil as it doesn't make their hair greasy or cause hair fall.
KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.
Topical melatonin was found to significantly increase hair density and decrease scalp conditions like seborrheic dermatitis. The user is considering using it alongside finasteride and oral minoxidil for treating hair loss and scalp health.
The conclusion of the conversation is that the user, PirateBeastBaby, had good results with microneedling for hair loss after using oral finasteride and topical minoxidil 20 years ago. They believe that microneedling was the gamechanger for their hair growth.
User experienced hair regrowth and no side effects after 10 weeks on 0.25mg finasteride daily, along with biotin, collagen, micro-needling, and hair oil. They stopped minoxidil due to inconvenience and noticed initial shedding but now see more fullness.
The user experienced significant hair growth and density improvement over nine months using 1 mg finasteride daily, initially 5% topical minoxidil, then transitioning to 2.5 mg and later 5 mg oral minoxidil, along with weekly microneedling. Noticeable changes were observed after three months, with the most significant progress by month nine.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.